• Medicenna flagged new survival analysis for bizaxofusp in unresectable IDH-wildtype recurrent glioblastoma selected for an oral presentation.
• Results have not been presented yet; the readout is scheduled for Nov. 13, 2026 at the Society for Neuro-Oncology annual meeting.
• Analysis compares outcomes to an external control arm, aiming to support positioning in the intended Phase 3 population.
• Oral slot signals rising clinician interest, potentially strengthening partnering prospects and the program’s strategic value in recurrent glioblastoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240700PRIMZONEFULLFEED9832694) on September 24, 2026, and is solely responsible for the information contained therein.